A practical reference on HPLC-MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-19. Anything still debated is marked as such rather than presented as settled.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
C12H22O11 + H2O → 2 C6H12O6 Heterolactic fermentation is in a sense intermediate between lactic acid fermentation and other types, e.g. alcoholic fermentation. Reasons to go further and convert lactic acid into something else include:
== History == In 1986, Sony introduced a smectic light valve LCD laser projector that could display high resolutions up to 8K resolution (8000×10,000). In 1995, NHK Science & Technology Research Laboratories began research and development on a Super Hi-Vision UHDTV system as a successor to their Hi-Vision HDTV system. In 2000, JVC introduced the first 4K resolution video projector, a D-ILA digital cinema projector. In 2001, the first liquid-crystal displays (LCDs) capable of displaying 4K content were the IBM T220/T221 LCD monitors for computers.
Bone morphogenetic proteins (BMPs) are a group of growth factors also known as cytokines and as metabologens. Professor Marshall Urist and Professor Hari Reddi discovered their ability to induce the formation of bone and cartilage, BMPs are now considered to constitute a group of pivotal morphogenetic signals, orchestrating tissue architecture throughout the body. The important functioning of BMP signals in physiology is emphasized by the multitude of roles for dysregulated BMP signalling in pathological processes. Cancerous disease often involves misregulation of the BMP signalling system. Absence of BMP signalling is, for instance, an important factor in the progression of colon cancer, and conversely, overactivation of BMP signalling following reflux-induced esophagitis provokes Barrett's esophagus and is thus instrumental in the development of esophageal adenocarcinoma. Recombinant human BMPs (rhBMPs) are used in orthopedic applications such as spinal fusions, nonunions, and oral surgery. rhBMP-2 and rhBMP-7 are Food and Drug Administration (FDA)-approved for some uses. rhBMP-2 causes more overgrown bone than any other BMPs and is widely used off-label.
The researchers have set out to answer possible questions from teachers using the program, highlight some minimum recommended training requirements for the software, suggest some "hints and tips" for teaching ideas, explain the importance of performing more studies / trials with the program, overview randomised controlled trial usage of the software, and highlight the importance of obtaining feedback from lesson participants. The recommendations seem to be straightforward and should help in formalising training with the program, as well as in the development of a network of teachers "accredited" to give lessons using the software.
Aquinas’ attribution of rational capacity to the immaterial soul allowed him to claim that disembodied souls could retain their rational capacity as his identification of the soul's individual act of existence allowed him to claim that personal immortality is natural for human beings. Aquinas was also adamant that disembodied souls were in an unnatural state and that the perfection of heaven includes God miraculously enabling the soul to function once again as a substantial form by reanimating matter into a living body as promised by the doctrine of the resurrection of the dead.
Sources: en.wikipedia.org
6-pyruvoyltetrahydropterin + 2 glutathione The 3 substrates of this enzyme are pyrimidodiazepine, glutathione disulfide, and H2O, whereas its two products are 6-pyruvoyltetrahydropterin and glutathione. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH group of donors with a disulfide as acceptor. The systematic name of this enzyme class is pyrimidodiazepine:glutathione-disulfide oxidoreductase (ring-opening, cyclizing). Other names in common use include PDA synthase, pyrimidodiazepine:oxidized-glutathione oxidoreductase (ring-opening,, and cyclizing). This enzyme participates in glutathione metabolism.
The largest and sole study employing bicalutamide, an industry-sponsored, phase II, multicenter, international, open-label, single-arm clinical trial known as the Bicalutamide and Anastrozole Treatment of Testotoxicosis (BATT) study, assessed the combination of 12.5 to 100 mg/day bicalutamide and 0.5 to 1 mg/day anastrozole over a period of 12 months in 14 young boys with FMPP. The mean age of the boys was 4 ± 2 years, with a range of 2 to 9 years of age. At baseline, the boys weighed 23 ± 6 kg (52 ± 12 lbs) on average, with a range 17 to 35 kg (37 to 77 lbs). Mean total levels of testosterone in the boys were 277 ± 208 ng/dL at baseline and increased to 523 ± 258 ng/dL at 6 months and 427 ± 243 ng/dL at 12 months. Mean total levels of estradiol in the boys were 3.8 pg/mL at baseline and were relatively unchanged at 6 and 12 months (2.5 pg/mL and 3.5 pg/mL, respectively). The dosage of bicalutamide was initiated at 12.5 mg/day and was then increased, with adjustment as necessary to maintain trough circulating (R)-bicalutamide concentrations within a target range of 5 to 15 μg/mL. This range is similar to (R)-bicalutamide levels achieved with approximately 30 to 100 mg/day bicalutamide in adult men with prostate cancer. The mean final dosage of bicalutamide in the boys at 12 months was 60 ± 29 mg/day, with 86% of the boys on either 50 or 100 mg/day bicalutamide. Levels of (R)-bicalutamide were proportional to dosage and did not appear to be related to the age or weight of the boys.
== Relations == The attached or orbital margins are connected to the circumference of the orbit by the orbital septum. The lateral angles are attached to the zygomatic bone by the lateral palpebral raphe. The medial angles of the two plates end at the lacrimal lake, and are attached to the frontal process of the maxilla by the medial palpebral ligament). The sulcus subtarsalis is a groove in the inner surface of each eyelid. Along the inner margin of the tarsus are modified sebaceous glands known as tarsal glands (or meibomian glands), aligned vertically within the tarsi: 30 to 40 glands in the upper lid, and 20 to 30 in the lower lid, which secrete a lipid-rich product which helps keep the lacrimal secretions or tears from evaporating too quickly, thus keeping the eye moist.
=== FCPA bribery lawsuits === From 2005 to 2010, Bio-Rad subsidiaries made bribes to foreign government officials, and made other payments intentionally ignoring the high likelihood of bribery. The bribes were estimated to have made $35.1 million profit for Bio-Rad, primarily from sales in Russia, Vietnam, and Thailand:
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.